πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 13 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11702389

Piperidine derivatives as HDAC1/2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11542242

Substituted piperazines as selective HDAC1,2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10968180

Piperidine derivatives as HDAC1/2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10858323

HDAC inhibitors for the treatment of diabetic peripheral neuropathy

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10774056

Substituted piperazines as selective HDAC1,2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10385031

Substituted piperazines as selective HDAC1,2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10358421

Piperidine derivatives as HDAC1/2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10239837

Piperidine derivatives as HDAC1/2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10125131

Selective HDAC3 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10040769

HDAC inhibitors for the treatment of diabetic peripheral neuropathy

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9957259

Selective HDAC1 and HDAC2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9790180

Piperidine derivatives as HDAC1/2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9765066

Selective HDAC1 and HDAC2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted